The patent covers the use of a lipase enzyme to digest dietary fats-which in turn results in the reduction of triglyceride levels in the bloodstream.
Enzymes specialist Bio-Cat Inc. (Troy, VA) has been granted a U.S. patent covering the use of a lipase enzyme to digest dietary fats-which in turn results in the reduction of triglyceride levels in the bloodstream.
Ed Schuler, the company’s CEO, says, “High triglycerides are a major problem for many people, and we knew the lipase enzyme had the ability to break the fats down. Our innovation is demonstrating the complete breakdown of fats during digestion in the stomach. This led to further observations where blood triglycerides were substantially reduced in initial test cases.”
The company says that the innovative concept to use lipase to reduce triglycerides started with the company’s previous investigations, for which it received a 2011 U.S. patent. That patent looked at using an enzyme mixture including lipase to help with digestion of fats and other materials in the diet, and to increase nutrient absorption, in people affected with pancreatic insufficiency, cystic fibrosis, and other similar ailments. That 2011 patent, No. 8,071,089, is titled “A Composition With a Fungal (Yeast) Lipase and Method For Treating Malabsorption in Cystic Fibrosis As Well As People Suffering From Pancreatic Lipase Insufficiency.”
The company says it will further pursue clinical studies investigating the benefits of the lipase enzyme for both conditions.
The new triglycerides patent is No. 8,268,305 and is titled “Methods and Compositions to Reduce Serum Levels of Triacylglycerides in Human Beings Using a Fungal Lipase.”
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.
Recent review makes the case for testing omega-3 fatty acid levels in humans
May 23rd 2024The article commissioned by The Global Organization for EPA and DHA Omega-3s (GOED) reviewed the state of omega-3 fatty acid testing, highlighting the value of testing and the commercially available options for diagnostic testing.
Epax launches concentrated oil that combines omegas 3, 9, and 11
May 10th 2024The blend of long-chain polyunsaturated fatty acids and long-chain monounsaturated fatty acids combines the heart and brain health benefits of omegas-3s with the skin and metabolic health benefits of omegas 9 and 11.